PPARG and neoplasm: Combination of radiotherapy with the PPARγ agonist rosiglitazone enhanced the effectiveness of radiotherapy against tumor angiogenesis, distant metastasis formation, and tumor recurrence in animal models with subcutaneous breast or colon cancer cell implantation [65].